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Abstract Treatment of U937 cells with various apoptosis-
inducing agents, such as TNFK and L-D-arabinofuranosylcyto-
sine (ara-C) alone or in combination with the phorbol ester 12-O-
tetradecanoylphorbol-13-acetate (TPA), bryostatin 1 or cyclo-
heximide, causes proteolytic cleavage of protein kinase CW
(PKCW) between the regulatory and catalytic domain, generating
a 62 kDa catalytic fragment of the kinase. The formation of this
fragment is effectively suppressed by the caspase-3 inhibitor Z-
DEVD-FMK. In accordance with these in vivo data, treatment of
recombinant PKCW with caspase-3 in vitro results also in the
generation of a 62 kDa fragment (p62). Treatment of several
aspartic acid to alanine mutants of PKCW with caspase-3 resulted
in an unexpected finding. PKCW is not cleaved at one of the
typical cleavage sites containing the motif DXXD but at the
atypical site CQND378/S379. The respective fragment (amino
acids 379^912) was expressed in bacteria as a GST fusion
protein (GST-p62) and partially purified. In contrast to the
intact kinase, the fragment does not respond to the activating
cofactors TPA and phosphatidylserine and is thus unable to
phosphorylate substrates effectively.
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1. Introduction
Human protein kinase C (PKC) W (and its mouse homolog
PKD) is a phospholipid-dependent, Ca2-independent serine/
threonine protein kinase which, like the c- and n-type PKC
isozymes (for reviews, see [1^5]), is stimulated by diacylglycer-
ol (DAG) or phorbol esters but di¡ers from the other PKCs
in some structural and enzymatic properties [6^13]. PKCW
contains a pleckstrin homology (PH) domain, two unique
amino-terminal hydrophobic domains and it lacks the typical
pseudosubstrate motif. Moreover, PKCW fails to phosphoryl-
ate several PKC substrates and to be inhibited by a PKC
speci¢c inhibitor. Also, the mechanism of activation of
PKCW appears to be di¡erent from that of the other DAG-
activated PKCs. The cysteine-rich regions [14], the PH do-
main [15] and possibly an acidic domain [16,17] might play
a role in the induction or suppression of PKCW activity. In
contrast to other PKCs [18^22], the role of phosphorylation
of PKCW for catalytic competence and activity of the kinase is
not known. It has been suggested, however, that PKCW is
phosphorylated and activated by other members of the PKC
family [23]. The cellular functions of PKCW are not clear yet.
The activation of the caspase system is a critical event in
apoptosis [24^26]. A number of signal transduction kinases,
including several PKC isoenzymes, are subject to caspase-
mediated breakdown. This results in the production of a cat-
alytically active fragment of some kinases, whereas several
other kinases are inactivated. For example, degradation
upon induction of apoptosis of MEKK-1 [27^29], PKN [30],
PKCN [31^33], PKCO [33] and PKCa [33] generates an active
fragment each, whereas Raf-1 [34], Akt [34] and PKCj [35]
are inactivated during apoptosis. This is consistent with a
model proposing the existence of pro-apoptotic and anti-
apoptotic (pro-survival) kinases that are activated and inacti-
vated, respectively, upon induction of apoptosis. Here, we
show that, similarly to other PKCs, PKCW undergoes speci¢c
proteolytic cleavage by caspases-3 upon induction of apopto-
sis in U937 cells, resulting in a 62 kDa catalytic fragment
(p62).
2. Materials and methods
2.1. Reagents
12-O-Tetradecanoylphorbol-13-acetate (TPA) was supplied by Dr.
E. Hecker, German Cancer Research Center (Heidelberg, Germany),
and Go«6983 by Goedecke AG (Freiburg, Germany). Bryostatin 1 was
provided by Dr. G.R. Pettit, State University of Arizona (Tempe, AZ,
USA. Syntide 2 was synthesized by Dr. R. Pipkorn, German Cancer
Research Center (Heidelberg, Germany). Recombinant PKCW was
expressed in a baculovirus-infected insect cell system as described
previously [36].
Other materials were bought from the following companies: active
human recombinant caspase-3 from Pharmingen (Hamburg, Ger-
many); caspase-3 inhibitor Z-DEVD-FMK from Calbiochem
(Schwalbach, Germany); bovine brain L-K-phosphatidylserine (PS),
cycloheximide and L-D-arabinofuranosylcytosine (ara-C) from Sigma
(Munich, Germany); [Q-32P]ATP (speci¢c activity, 5000 Ci/mmol)
from Hartmann Analytic (Braunschweig, Germany); L-[35S]meth-
ionine (speci¢c activity, 1000 Ci/mmol) from Amersham Buchler
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(Braunschweig, Germany); PKCW speci¢c polyclonal antibody sc-639
from Santa Cruz Biotechnology (Santa Cruz) and alkaline phospha-
tase-conjugated goat antibodies from Dianova (Hamburg, Germany);
K252a from Fluka Chemie A.G. (Neu-Ulm, Germany); thrombin
from Amersham Pharmacia (Freiburg, Germany); leupeptin and
aprotinin from Roche Diagnostic (Mannheim, Germany).
2.2. Cell culture
Human U937 myeloid leukemia cells were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum, 100 U/ml pen-
icillin, 100 Wg/ml streptomycin and 2 mM L-glutamine. Cells were
treated with various agents as indicated in the ¢gure legends.
2.3. Preparation of cell extracts and immunoprecipitation
Cells were washed twice with phosphate-bu¡ered saline (PBS) and
stored at 375‡C. Upon thawing, they were resuspended in lysis bu¡er
(20 mM Tris-HCl, pH 7.5, 10 Wg/ml aprotinin and 10 Wg/ml leupep-
tin). The cell suspension was kept on ice for 30 min. Upon centrifu-
gation at 100 000Ug for 35 min, the supernatant (cell extract) was
used for immunoprecipitation. The cell extract (1.5 mg protein) was
incubated with 14 Wg/ml of the anti-PKCW antibody sc-639 in lysis
bu¡er containing 150 mM NaCl (total volume 1 ml) at 4‡C for 1.5 h
and subsequently with 30 Wl of protein-A-agarose at 4‡C for 2 h. The
precipitate was dissolved in 80 Wl phosphorylation bu¡er and phos-
phorylated as described below under Section 2.8.
Fig. 1. Proteolytic cleavage of PKCW in U937 cells upon treatment with various apoptosis-inducing agents. A: U937 cells remained untreated
or were treated for 6 h with 10 WM ara-C alone or together with 300 nM TPA or 300 nM bryostatin or with 50 ng/ml TNFK alone or together
with TPA or bryostatin (300 nM each). In another experiment, U937 cells were pretreated with 5 Wg/ml cycloheximide (CHX) for 30 min and
then treated with 50 ng/ml TNFK for 6 h. Cells were washed twice with PBS, resuspended in sample bu¡er and analyzed by SDS-PAGE.
PKCW and its fragment p62 (see arrows) were detected by immunoblotting using the PKCW speci¢c antibody sc-639 raised against a C-terminal
peptide of PKCW. B: Cycloheximide (CHX) and TNFK were applied to the cells as above for various times. PKCW and p62 were visualized by
immunoblotting (see arrows). C: Cells remained untreated or were treated with ara-C plus bryostatin as in A. Cell extracts were immunopreci-
pitated and the precipitates phosphorylated in the absence or presence of PS/TPA and applied to SDS-PAGE as described in the Section 2.
Phosphorylated PKCW and p62 were visualized by autoradiography (see arrows). D: Upon pretreatment with 5 Wg/ml cycloheximide (CHX, 30
min), cells were treated for 6 h either with 50 ng/ml TNFK alone, TNFK plus 40 Wl of the solvent DMSO or TNFK plus 100 WM caspase-3 in-
hibitor Z-DEVD-FMK in 40 Wl DMSO. Preparation and processing of cell extracts were as in A.
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2.4. Cleavage of recombinant PKCW with caspase-3
Ten microliters of recombinant PKCW was incubated with and
without 16 Wg/ml recombinant caspase-3 at 37‡C for 15 min and the
reaction products were analyzed by immunoblotting or phosphoryl-
ated as described below under Section 2.8 and analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(7.5%) and autoradiography of the gels.
2.5. In vitro translation of PKCW wild-type and mutants
The PKCW mutants (D391/A), (D349/A), (D388/A, D391/A),
(D386/A), (D384/A) and (D378/A) were generated in two stages using
the ‘overlap extension’ method as described previously [21].
[35S]Methionine-labelled proteins (PKCW wild-type and mutants)
were synthesized by coupled transcription and translation reaction
using the ‘TNT Coupled Reticulocyte Lysate System’ (Promega). La-
belled proteins were incubated with and without 16 Wg/ml caspase-3 at
37‡C for 15 min. Reaction products were analyzed by SDS-PAGE
(7.5%) and autoradiography of the gels.
2.6. Bacterial expression of recombinant GST-p62
The p62 fragment of PKCW (amino acid residues 379^912) was
ampli¢ed from the full-length PKCW cDNA, cloned into the bacterial
expression plasmid pGEX-2T (Pharmacia), expressed as a GST fusion
protein and puri¢ed by a⁄nity chromatography on glutathione beads.
This construct is termed GST-p62. Primers used to amplify this region
were 5P-GGGGGATCCAGTGGCGAGATGCAAGATCCAGACC-
CA and 5P-GGGGAATTCAGAGGATGCTGACACGCTCACC-
GAGGGCTT. The GST fusion protein of the fragment 392^912
was prepared in a similar way. GST was removed by treating the
fusion proteins with 5 U/ml thrombin at room temperature for 2 h.
2.7. Protein kinase assay
Phosphorylation reactions with syntide 2 as substrate were carried
out as described previously [12].
2.8. Autophosphorylation and phosphorylation of aldolase
Phosphorylation reactions were performed essentially as described
for the protein kinase assay [12], but 37 WM ATP containing 8 instead
of 1 WCi [Q-32P]ATP was added. Moreover, the substrate was omitted
(autophosphorylation) or aldolase (5 Wg) was added instead of syntide
2 as a substrate. Proteins of the reaction mixture were separated by
SDS-PAGE and visualized by autoradiography.
3. Results and discussion
3.1. Generation of a 62 kDa fragment of PKCW in vivo and in
vitro
We noticed that between the regulatory and catalytic do-
main, human PKCW contains two cleavage motifs of the clas-
sical type DXXD for the cysteinyl aspartate speci¢c protease
caspase-3. Therefore, we became interested in the question
whether induction of apoptosis and, in this context, activation
of caspase-3 might result in a speci¢c fragmentation of PKCW.
U937 cells were treated with ara-C or TNFK, i.e. agents
known to induce apoptosis in these cells [37^39]. These treat-
ments resulted in the generation of a PKCW fragment with an
apparent molecular weight of 62 kDa (p62), as demonstrated
by immunoblotting using an antibody directed against a C-
terminal peptide of PKCW (Fig. 1A). The addition of bryo-
statin or TPA as well as the pretreatment for 30 min with
cycloheximide augmented the e¡ect of both agents on the
fragmentation of PKCW (Fig. 1A). Bryostatin and TPA alone
were inactive in this respect (not shown). However, as previ-
ously described [13], these compounds caused a mobility shift
of PKCW, indicating its activation and (auto)phosphorylation.
The combined e¡ect of cycloheximide and TNFK was ob-
served as early as 1.5 h upon treatment and reached a max-
imum at around 6 h (Fig. 1B). The fragment p62 was still able
to autophosphorylate (Fig. 1C). In contrast to the intact
PKCW, however, its autophosphorylation could not be in-
creased by PS/TPA.
The peptide Z-DEVD-FMK, an inhibitor of caspase-3, sup-
pressed the TNFK/cycloheximide-induced cleavage of PKCW
(Fig. 1D), indicating that caspase-3 is the responsible enzyme.
This conclusion was supported by the exclusive formation of a
62 kDa fragment upon treatment of recombinant PKCW from
baculovirus-infected insect cells in a cell-free system with casp-
ase-3 for 15 min (Fig. 2A). Like the p62 fragment found in
cells, the fragment produced by caspase-3 in vitro showed
autophosphorylation that did not respond to PS/TPA (Fig.
2B). Another fragment of about 35 kDa was found only in
vivo (Fig. 1A,B) but not in the cell-free system (Fig. 2A),
indicating that it was not due to cleavage by caspase-3.
3.2. Identi¢cation of the cleavage site of PKCW for caspase-3
To identify the caspase-3 cleavage site, we produced various
aspartic acid to alanine mutants of PKCW using an in vitro
transcription/translation system and treated the cell extracts
thus obtained with caspase-3. The proteolytic cleavage was
determined by autoradiography of the 35S-labelled proteins
upon SDS-PAGE (Fig. 3). PKCW contains a typical caspase-
3 cleavage motif, i.e. D388HED391, which upon cleavage at
D391/A392 would give rise to a 62 kDa fragment. However,
the D391A and D391A/D388A mutants were cleaved by casp-
ase-3 as e¡ectively as the wild-type (Fig. 3). Mutation of
Fig. 2. Proteolytic cleavage of recombinant PKCW by treatment
with caspase-3 in a cell-free system. A: Ten microliters of recombi-
nant PKCW (a c-myc epitope-tagged PKCW expressed in baculovi-
rus-infected insect cells, see [36]) was incubated with or without 16
Wg/ml caspase-3 at 37‡C for 15 min. Upon SDS-PAGE, PKCW and
its fragment p62 were visualized by immunoblotting (see arrows). B:
Recombinant PKCW was treated as in A. Subsequently, the mixture
was phosphorylated in the absence or presence of 10 Wg PS and 100
nM TPA as described in Section 2. Phosphorylated PKCW and p62
were visualized by autoradiography (see arrows).
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another potential cleavage site for caspase-3, i.e. D349/S350,
was equally ine¡ective (not shown). Therefore, we mutated
other aspartic acid residues in this region, i.e. D378, D384
and D386, even though these are atypical cleavage sites for
caspase-3. Whereas mutation of D384 and D386 to alanine
did not a¡ect cleavage, the D378/A mutant was completely
resistant to caspase-3 (Fig. 3). This demonstrated that
PKCW is cleaved by caspase-3 at the atypical site CQND378/
S379. Atypical cleavage sites for caspase-3 have been reported
previously [40^42].
3.3. Expression and characterization of the GST-tagged
fragment 379^912 (GST-p62)
Two GST-tagged fragments were expressed in bacteria and
partially puri¢ed by a⁄nity chromatography, i.e. the fragment
379^912 corresponding to the atypical site D378/S379 and the
fragment 392^912 corresponding to the typical caspase-3 site
D391/A392. Upon removal of the GST-tag with thrombin, the
recombinant fragments were compared with the in vivo and in
vitro fragments of PKCW by immunoblotting. Fig. 4 shows
that the latter fragments are identical in size with the recombi-
nant fragment 379^912 but not with the fragment 392^912,
indicating that caspase-3 indeed cleaves PKCW at the atypical
site D378/S379 in vitro and in vivo.
The GST-tagged fragment 379^912 (GST-p62) was further
characterized. Compared to intact PKCW, GST-p62 exhibited
Fig. 5. Kinase activity of the recombinant fragment GST-p62. A:
Equal amounts (as estimated by immunoblotting) of PKCW (5 Wl)
or GST-p62 (2 Wg protein) were used to phosphorylate syntide 2
and incorporation of phosphate was determined as described in Sec-
tion 2. Phosphorylation of 5 Wg syntide 2 was performed in the ab-
sence or presence of 10 Wg PS/100 nM TPA. B: Five micrograms of
aldolase was phosphorylated with equal amounts of PKCW (3) or
GST-p62 (2) in the presence of PS/TPA as described in Section 2.
Phosphorylation with GST-p62 is shown also in the absence of PS/
TPA (1) to allow for a comparison of the autophosphorylation of
the recombinant fragment in the absence and presence of PS/TPA.
Upon SDS-PAGE, phosphorylated proteins were visualized by auto-
radiography.
Fig. 4. Comparison of recombinant fragments of PKCW with the
p62 fragments produced in vitro and in vivo. Upon removal of the
GST-tag by thrombin treatment (see Section 2), the bacterially ex-
pressed recombinant fragments (379^912) and (392^912) of PKCW
were applied to SDS-PAGE. In addition, caspase-3-treated PKCW
(p62 in vitro, see Fig. 2A) and an extract from cells treated with cy-
cloheximide plus TNFK (p62 in vivo; see Fig. 1A,B) were applied
to the gel. The recombinant fragments and p62 were visualized by
immunoblotting.
Fig. 3. Proteolytic cleavage of in vitro transcribed/translated PKCW
wild-type (WT) and mutants by caspase-3. PKCW wild-type and mu-
tants were synthesized in an in vitro transcription/translation system
as described in Section 2. Various aspartic acid residues (D) were
mutated to alanine (A) as indicated. The 35S-labelled proteins were
incubated with or without 16 Wg caspase-3 at 37‡C for 15 min.
Upon SDS-PAGE, labelled proteins were visualized by autoradiog-
raphy. PKCW and p62 are indicated by arrows. In some experi-
ments, a slower migrating form of PKCW (possibly phosphorylated)
is visible that has been observed previously [13].
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an around 15 times higher kinase activity in the absence of PS
and TPA. In contrast to PKCW, however, this basal kinase
activity of the fragment could not be increased by PS/TPA,
supporting the data on autophosphorylation of p62 in vivo
(Fig. 1C) and in vitro (Fig. 2B). In fact, in the presence of PS/
TPA, the fragment was much less active than intact PKCW, as
shown by phosphorylation of syntide 2 and aldolase (Fig. 5).
Removal of the GST-tag did not a¡ect the kinase activity of
the fragment (not shown). Moreover, the fragment p62 was
found to be more sensitive than PKCW towards the kinase
inhibitors K252a (IC50 of 0.6 nM for the fragment as com-
pared to 7 nM for the intact PKCW) and Go«6983 (IC50 of
2 WM versus 20 WM for intact PKCW).
Considering these results, it is conceivable that the PKCW
fragment exhibits speci¢c functions di¡ering from those of the
intact enzyme. In this context, it should be noted that local-
ization experiments using GFP constructs indicate a di¡eren-
tial subcellular localization of PKCW and its fragment (Ha«us-
sermann et al., unpublished observation). It has been reported
that PKCW might protect cells against apoptosis [43]. Thus,
proteolytic cleavage of PKCW upon induction of apoptosis
possibly would abolish the protective e¡ect. Moreover, the
generated fragment might somehow support the apoptotic
process (compare e.g. PKCN [34]).
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